Ultrasound-guided pericapsular nerve group (PENG) block for early analgesia in elderly patients with hip fractures: a single-center prospective randomized controlled study.

"Declarations Ethics approval and consent to participateThe study conformed to the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of The Second Affiliated Hospital of Xuzhou Medical University ([2022] 052501), and this study was registered with the Chinese Clinical Trial Testing Center (ID: ChiCTR2200062400). All participants gave written informed consent.All authors listed meet the authorship criteria according to the latest guidelines of the International Committee of Medical Journal Editors, and that all authors are in agreement with the manuscript. Written informed consent was taken from all the patients. This study was registered in the Chinese Clinical Trial Testing Center (ID: ChiCTR2200062400,04.08.2022) Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding The authors received no funding for this work."

"The study conformed to the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of The Second Affiliated Hospital of Xuzhou Medical University ([2022] 052501), and this study was registered with the Chinese Clinical Trial Testing Center (ID: ChiCTR2200062400,04.08.2022). Written informed consent was obtained from all the subjects participating in the trial. The study plan was to enroll patients beginning in June, but patients were actually recruited between August 2022 and December 2022 after clinical registration. Inclusion criteria: ① Patients with an imaging diagnosis of hip fracture; ② Age ≥60 years old; ③ Dynamic NRS scores ≥4 points; ④ BMI: 18-30 kg/m2. Exclusion criteria: ① Patients with allergies to the drug used in this experiment; ② Patients with local or systemic infection; ③ Patients with coagulopathy; ④ Patients with severe cardiopulmonary insufficiency; ⑤ Patients with a history of ipsilateral hip surgery; ⑥ Patients with mental, language, communication, or hearing impairment; ⑦ Patients who refused to participate in this trial; ⑧ Patients with multiple systemic injuries. Conclusions: Compared with intravenous flurbiprofen, ultrasound-guided PENG block provides better early analgesic effects in elderly patients with hip fractures, and a PENG block is safe for elderly patients with hip fractures after hospitalization.: Trial registration: This study was registered in the Chinese Clinical Trial Testing Center (ID: ChiCTR2200062400). Declarations: Ethics approval and consent to participateThe study conformed to the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of The Second Affiliated Hospital of Xuzhou Medical University ([2022] 052501), and this study was registered with the Chinese Clinical Trial Testing Center (ID: ChiCTR2200062400). All participants gave written informed consent.All authors listed meet the authorship criteria according to the latest guidelines of the International Committee of Medical Journal Editors, and that all authors are in agreement with the manuscript. Written informed consent was taken from all the patients. This study was registered in the Chinese Clinical Trial Testing Center (ID: ChiCTR2200062400,04.08.2022): Consent for publicationNot applicable.: Competing interestsThe authors declare no competing interests. Ethics approval and consent to participate: The study conformed to the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of The Second Affiliated Hospital of Xuzhou Medical University ([2022] 052501), and this study was registered with the Chinese Clinical Trial Testing Center (ID: ChiCTR2200062400). All participants gave written informed consent.: All authors listed meet the authorship criteria according to the latest guidelines of the International Committee of Medical Journal Editors, and that all authors are in agreement with the manuscript. Written informed consent was taken from all the patients. This study was registered in the Chinese Clinical Trial Testing Center (ID: ChiCTR2200062400,04.08.2022)"